Previous 10 | Next 10 |
– Vutrisiran Met Primary and All Secondary Endpoints at 9 Months, with Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), and Gait Speed, Relative to Placebo – – Majority of Patients Showed Reversal of Disease Manif...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 am ET. This presentation will include an...
- Strong Commercial and Medical Team in Place to Execute on Three Ongoing Global Launches and Advancement of Innovative Pipeline of RNAi Therapeutics – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appoint...
Dicerna is right behind Alnylam in the RNAi space. Its lead candidate is nedosiran targeting primary hyperoxaluria. This is a solid candidate, looking to accumulate at better prices. For further details see: Dicerna: Great Value RNAi Runner Up
− Product and Pipeline Goals Include Execution on Four Commercial Brands, One New NDA Filing, Two Phase 3 Data Readouts, Amongst Other Milestones – – New Clinical Data Presented from Phase 1 Monotherapy Study of ALN-AGT Show Mean Reduction in 24-Hour Systo...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com , on December 15 and 16, 2020. In additi...
Centogene N.V. (NASDAQ: CNTG) teams up with Alnylam Pharmaceuticals (NASDAQ:ALNY) to launch a new joint clinically screening program targeting the at-risk population for hereditary TransthyRetin-related Amyloidosis (ATTRv).In addition to the genetic screening of the patients, the study w...
− Company Also Introduces Inaugural ‘Rare Disease Trend Report’ Providing Insights Gleaned Through Interviews and Research with Payers − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two n...
Despite delays due to travel restrictions for inspections by the Food and Drug administration, the agency is still approving drugs unrelated to the COVID-19 pandemic after virtual review of manufacturing documents. In this video from Motley Fool Live recorded on Nov. 30, Healthcare ...
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels PITTSBURGH , Dec. 3, 2020 /PRNewswire/ -- PANTHERx ® Rare Pharmacy an...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...